Santalum album ointment - Santalis Healthcare

Drug Profile

Santalum album ointment - Santalis Healthcare

Alternative Names: Albuterpenoid -Santalis Healthcare ViroXis; East Indian sandalwood oil - Santalis Healthcare; EISO - Santalis Healthcare

Latest Information Update: 29 Jan 2016

Price : $50

At a glance

  • Originator ViroXis
  • Developer Santalis Healthcare Corporation; ViroXis
  • Class Anti-infectives; Phytotherapies; Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Warts
  • Discontinued Acne; Mycoses; Skin and soft tissue infections; Skin cancer; Wounds

Most Recent Events

  • 25 Jan 2016 ViroXis is now called Santalis Healthcare
  • 11 Jan 2016 Santalis Pharmaceuticals plans a phase III trial for Warts (In children) in USA
  • 15 Jun 2015 Santalum album ointment is still in phase II trials for Warts in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top